DOBUTamine in 5% Dextrose Injection
Lack of Assurance of Sterility: Confirmed report of leaking in the primary container.
1,803 recalls · Class II, newest first
Lack of Assurance of Sterility: Confirmed report of leaking in the primary container.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Marketed without an Approved NDA/ANDA.
Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.